Flmodafinil

Atypical Dopamine Transporter Inhibition#

Flmodafinil is the bis(4-fluoro) ring-substituted analog of modafinil and acts primarily as a selective, atypical dopamine reuptake inhibitor at the dopamine transporter (DAT). The fluorine substitutions at the para positions of both phenyl rings increase DAT affinity relative to the unsubstituted modafinil scaffold while preserving the "atypical" binding geometry that separates this chemotype from cocaine-like stimulants.

"The bis-para-fluoro analogue (CRL-40,940) exhibited increased affinity at the dopamine transporter compared to the parent compound modafinil, while retaining an atypical inhibitor profile." — Cao J. et al., ACS Medicinal Chemistry Letters, 2011

Practically, this is why subjects report flmodafinil as "cleaner" and more motivationally focused than the same mg of modafinil — the compound is sitting on DAT harder, but in a conformation that doesn't trigger the reinforcement/euphoria profile of classic psychostimulants.

Tonic Rather Than Phasic Dopamine Elevation#

The way flmodafinil elevates extracellular dopamine is as important as how much. Voltammetry and microdialysis work in the mouse nucleus accumbens shell shows that CRL-40,940 stabilizes DAT in an inward-occluded conformation, producing slow, sustained dopamine elevation rather than the sharp phasic surges that drive the abuse liability of cocaine, amphetamine, or methylphenidate.

"CRL-40,940 displayed atypical DAT blocker properties, promoting sustained extracellular dopamine without the sharp phasic spikes associated with classic psychostimulants like cocaine." — Keighron JD et al., ACS Chemical Neuroscience, 2019

The downstream result is attentional gain and motivational drive without the crash. This is the mechanistic underpinning of the cutting-phase use case: sustained PFC and striatal dopamine tone blunts appetite, rescues the anhedonia of a deep deficit, and makes diet adherence possible without the rebound binge that follows a stimulant peak-and-crash curve.

Downstream Wake-Promoting Circuitry#

Like the modafinil parent scaffold, flmodafinil's dopaminergic signal propagates into the classical arousal circuitry: indirect activation of histaminergic tuberomammillary neurons, elevation of hypothalamic orexin/hypocretin tone, and modest increases in cortical norepinephrine and glutamate. The net output is prolonged wakefulness with preserved cognitive performance — and the preclinical potency data suggest flmodafinil is meaningfully more efficient at this than its parent.

"NLS-4 significantly increased total wake time and decreased non-REM sleep in rats with roughly half the dose required for modafinil, and notably did not produce compensatory sleep rebound." — Luca G. et al., Frontiers in Neuroscience, 2018

The absence of compensatory sleep rebound is the practical distinction from caffeine and from classic stimulants: the "sleep debt" model doesn't quite apply. Subjects report same-night sleep is achievable if the dose window closes by late morning, consistent with the ~10–15h extrapolated half-life.

Clean Hepatic Profile (No CYP Induction)#

A mechanistically underappreciated advantage: flmodafinil does not appear to meaningfully induce CYP3A4 or inhibit CYP2C19 the way modafinil does. Modafinil's enzyme-induction profile is the reason it tanks hormonal contraceptive efficacy and interacts with a long list of orals (including several AAS-relevant 17-alpha-alkylated compounds that depend on hepatic clearance kinetics). The fluorinated analog metabolizes along a different route and does not appear to drive the same induction cascade — a non-trivial upgrade for anyone stacking a eugeroic with orals on cycle. The data here is thin enough that it should be treated as a working assumption rather than a settled fact, but it tracks with what community users running both compounds consistently report.

Parent Compound, Not a Prodrug#

Unlike adrafinil (which is metabolized to modafinil in the liver), flmodafinil is delivered and active as the parent molecule. Analytical work by Dowling et al. confirmed the structural identity and also flagged that CRL-40,940 can thermally degrade in GC injectors to a tetraphenylethane byproduct — relevant for sourcing quality control but not for pharmacology.

"Thermal degradation of CRL-40,940 in analytical conditions highlights challenges in confirming sample identity, emphasizing the need for robust analytic testing for research chemical sourcing." — Dowling G. et al., Drug Testing and Analysis, 2017

The practical takeaway: onset is faster than adrafinil (no hepatic conversion step) and cleaner than modafinil (no enzyme-induction tail), which is why the non-medical nootropic community has gravitated to it as the more refined member of the family.

"CRL-40,940 (flmodafinil) is attracting interest among non-medical users for enhanced cognitive performance, though its safety profile in humans remains inadequately characterized." — Schifano F. et al., Drugs, 2022

Common (most users)#

• Headache — the most frequently reported effect, dose-dependent and typically emerging 3–5 hours post-dose. Responds well to aggressive hydration (aim for ~500ml water with the dose and another 500ml through the morning) and modest sodium. A pinch of salt in the morning water or a low-sugar electrolyte drink handles most cases. If headaches persist at 100mg, dropping to 50mg usually resolves them.
• Mild anxiety or sympathetic edge — that "wired" quality characteristic of dopaminergic wake-promoters. 200mg L-theanine taken alongside the dose is the near-universal community fix and takes the edge off without blunting focus. Avoid stacking with a second strong stimulant (high-dose caffeine, ephedrine) until the response to flmodafinil alone is mapped.
• Appetite suppression — useful during cutting phases, inconvenient on a bulk. Protein shakes and calorie-dense liquids are the workaround when food doesn't appeal. Not a thermogenic; the suppression is the fat-loss-adjacent effect.
• Insomnia — dosing after noon reliably wrecks sleep. The protocol calls for closing the dose window by ~10 AM; the split protocol (50mg AM + 50mg early afternoon) should cap at roughly 1 PM. 300mg magnesium glycinate in the evening offsets residual sympathetic carryover.
• Dry mouth, mild nausea — primarily at initiation. Dosing with a light breakfast rather than fully fasted smooths both.
• Irritability or emotional compression — the dopaminergic tone flattens affective range in some subjects. Usually benign and reverses within 24 hours of the last dose; if it persists, weekly frequency is too high.

Uncommon (dose-dependent or individual)#

• Elevated resting heart rate and blood pressure — modest at 50–100mg but climbs noticeably above 150mg. Users running flmodafinil alongside harsh orals, trenbolone, or an AAS cycle with untreated hypertension should monitor resting BP and HR. If resting BP trends above 140/90 or HR above 95, the dose is too high or the stack is too loaded.
• Jitter, tremor, tachycardia — above ~150mg this becomes common rather than rare. Drop to 100mg and layer L-theanine.
• Post-dose "flat day" — anhedonia and low motivation the day after a dosing day, characteristic of dopaminergic tolerance. Mitigation is frequency control: 1–3 days per week, not daily. If flat days appear at 2×/week, spread to 1×/week for a month.
• Tolerance drift — daily use past ~2–3 weeks produces the same dull, subthreshold response well-documented for chronic modafinil. Addressed by cycling off for 1–2 weeks rather than escalating the dose.

"NLS-4 significantly increased total wake time and decreased non-REM sleep in rats with roughly half the dose required for modafinil, and notably did not produce compensatory sleep rebound." — Luca et al., Frontiers in Neuroscience (2018)

The absence of rebound in preclinical work is reassuring, but it does not override the human reality that closing the dose window early preserves sleep architecture.

Rare but serious#

• Severe dermatologic reaction (Stevens-Johnson syndrome, TEN) — no published flmodafinil-specific cases exist, but modafinil carries a black-box warning for SJS/TEN and flmodafinil is a close structural analog. Any new rash, mucosal involvement, or flu-like prodrome warrants immediate discontinuation and medical evaluation. Do not restart.
• Precipitated psychosis or mania — dopaminergic agents can trigger episodes in susceptible individuals. Warning signs: pressured speech, grandiosity, paranoid ideation, sleep going from 5 hours to zero. Discontinue immediately.
• Cardiac event (arrhythmia, hypertensive crisis) — the risk is concentrated in subjects with pre-existing cardiovascular disease, LVH, or those stacking with MAOIs or high-dose sympathomimetics. Chest pain, palpitations beyond mild awareness, or syncope means stop and evaluate.
• Sample identity failures — not a pharmacologic risk per se, but the Dowling 2017 work documented that CRL-40,940 thermally degrades in GC injectors to a tetraphenylethane byproduct, complicating analytical confirmation. Bad sourcing can mean the capsule is not what the label claims.

"Thermal degradation of CRL-40,940 in analytical conditions highlights challenges in confirming sample identity, emphasizing the need for robust analytic testing for research chemical sourcing." — Dowling et al., Drug Testing and Analysis (2017)

Third-party HPLC testing (Janoshik, Energy Control) is the standard community safeguard.

Hard contraindications#

• Pre-existing cardiovascular disease, uncontrolled hypertension, LVH, or arrhythmia. A dopaminergic/adrenergic wake-promoter layered on a strained heart — particularly on cycle — is not a margin worth testing.
• MAOIs (phenelzine, tranylcypromine, selegiline at MAO-A doses). Mechanistically foreseeable hypertensive crisis. No dose is safe.
• History of psychosis, schizophrenia, or bipolar I. Dopaminergic agents precipitate episodes.
• Pregnancy. Modafinil is pregnancy category D with a documented congenital malformation signal; the analog is treated identically in the absence of clearing data. This line does not move.
• Afternoon dosing. Not a safety contraindication in the cardiac sense, but an absolute protocol rule — anything past ~noon compromises sleep, and chronic sleep compression is where the cognitive and cardiovascular edges of this compound turn ugly.
• Concurrent strong sympathomimetic stacks (high-dose amphetamines, ephedrine + caffeine + yohimbine combinations). Additive cardiovascular load without additive cognitive benefit.

Gender and PCT considerations#

Flmodafinil is non-hormonal. No androgen receptor, estrogen receptor, or HPG-axis activity has been documented. No effect on testosterone, LH, FSH, or prolactin is reported. No PCT is required, and no ancillaries are needed.

Female subjects should note that the parent modafinil scaffold reduces hormonal contraceptive efficacy via CYP3A4 induction. Flmodafinil reportedly lacks this induction, which is one of its real advantages over modafinil — but the human data is thin, and barrier backup during flmodafinil weeks remains the conservative call for subjects relying on oral contraceptives.

Dosing is not gender-specific. The 25–200mg ladder applies uniformly; smaller-frame subjects simply start at the low end (25–50mg) and titrate.